STOCK TITAN

APLS insider Form 144: 5,000 shares from restricted stock to be sold via Fidelity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice discloses a proposed sale of 5,000 common shares to be executed approximately on 08/18/2025 through Fidelity Brokerage Services LLC on NASDAQ with an aggregate market value of $139,000. The filing lists 126,289,910 shares outstanding for the class. The shares were acquired in two restricted stock vesting events from the issuer on 01/21/2024 (4,031 shares) and 01/28/2024 (969 shares), paid as compensation. The filer previously sold 5,000 shares on 06/16/2025 for $93,850 and 5,000 shares on 07/16/2025 for $97,750. The form includes broker and seller name/address details but lacks a named issuer in the filing text.

Positive

  • Acquisitions were disclosed as restricted stock vesting and paid as compensation, providing clear provenance of the shares
  • Broker and transaction details are provided (Fidelity Brokerage Services LLC; NASDAQ; sale date approximate)

Negative

  • Filing text does not state the issuer name within the provided content, limiting contextual assessment
  • Recent insider sales recorded (5,000 shares in June and 5,000 shares in July 2025), which may raise questions about continued selling pressure
  • No statement in the provided text about a 10b5-1 plan or filer’s relationship to the issuer, reducing clarity on whether sales follow a pre-established plan

Insights

TL;DR: Routine insider sale of a small block of vested restricted shares; disclosed clearly with recent prior sales noted.

The notice documents a proposed sale of 5,000 common shares with an aggregate market value of $139,000, originating from restricted stock vesting in January 2024 and characterized as compensation. Prior near-term sales of 5,000 shares in June and July 2025 are recorded with gross proceeds shown. For investors, this is a transparent, routine Rule 144 filing reflecting liquidity events from compensation; on its own it is unlikely to be material to company valuation given the share count disclosed. Absence of an explicit issuer name in the filing text limits contextual assessment of insider role and proportionate ownership.

TL;DR: Disclosure complies with Rule 144 requirements but provides limited context on insider ownership and plan status.

The form supplies acquisition dates, nature of acquisition (restricted stock vesting), broker details, and recent sale transactions, which supports regulatory transparency. However, the filing omits a clear issuer name within the provided content and does not state the filer’s relationship to the issuer or whether a 10b5-1 plan applies. Those omissions reduce the ability to evaluate governance implications or whether sales follow an established trading plan. As presented, the filing documents routine dispositions without explicit governance context.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for APLS disclose about the proposed sale?

The form discloses a proposed sale of 5,000 common shares to be sold approximately on 08/18/2025 through Fidelity on NASDAQ with an aggregate market value of $139,000.

How were the shares being sold on this Form 144 acquired?

The shares were acquired via restricted stock vesting from the issuer on 01/21/2024 (4,031 shares) and 01/28/2024 (969 shares) and were paid as compensation.

Has the filer sold other shares recently according to this filing?

Yes. The filing lists sales by David O. Watson of 5,000 shares on 06/16/2025 (gross proceeds $93,850) and 5,000 shares on 07/16/2025 (gross proceeds $97,750).

What exchange and broker are named for the proposed sale?

The proposed sale is to be executed on NASDAQ through Fidelity Brokerage Services LLC (900 Salem Street, Smithfield RI 02917).

Does the filing state the issuer’s total shares outstanding?

Yes. The filing lists 126,289,910 shares outstanding for the class associated with this sale.
Apellis Pharmace

NASDAQ:APLS

APLS Rankings

APLS Latest News

APLS Latest SEC Filings

APLS Stock Data

2.60B
106.62M
13.68%
105.74%
16.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM